NEW YORK, NY / ACCESSWIRE / March 2, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
AZN Shareholders Click Here: https://www.zlk.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=13232&wire=1
XOM Shareholders Click Here: https://www.zlk.com/pslra-1/exxon-mobil-corporation-loss-submission-form?prid=13232&wire=1
IQDNX Shareholders Click Here: https://www.zlk.com/pslra-1/infinity-q-diversified-alpha-fund-loss-submission-form?prid=13232&wire=1
* ADDITIONAL INFORMATION BELOW *
Astrazeneca Plc (NYSE:AZN)
AZN Lawsuit on behalf of: investors who purchased May 21, 2020 - November 20, 2020
Lead Plaintiff Deadline : March 29, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=13232&wire=1
According to the filed complaint, during the class period, Astrazeneca Plc made materially false and/or misleading statements and/or failed to disclose that: (a) initial clinical trials for the Company's COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca's clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.
Exxon Mobil Corporation (NYSE:XOM)
XOM Lawsuit on behalf of: investors who purchased February 28, 2018 - January 14, 2021
Lead Plaintiff Deadline : March 29, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/exxon-mobil-corporation-loss-submission-form?prid=13232&wire=1
According to the filed complaint, during the class period, Exxon Mobil Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) Exxon forced its employees to use unrealistic assumptions regarding the timelines for well drilling in the Permian Basin; (ii) the foregoing assumptions served to artificially inflate the value of the Company's well operations in the Permian Basin; (iii) the foregoing conduct, when revealed, subjected Exxon to a heightened risk of regulatory investigation and oversight; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Infinity Q Diversified Alpha Fund Institutional Class (NASDAQ:IQDNX)
IQDNX Lawsuit on behalf of: investors who purchased December 21, 2018 - February 22, 2021
Lead Plaintiff Deadline : April 27, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/infinity-q-diversified-alpha-fund-loss-submission-form?prid=13232&wire=1
According to the filed complaint, during the class period, Infinity Q Diversified Alpha Fund Institutional Class made materially false and/or misleading statements and/or failed to disclose that: (1) Infinity Q's Chief Investment Officer made adjustments to certain parameters within the third-party pricing model that affected the valuation of the swaps held by the Fund; (2) consequently, Infinity Q would not be able to calculate NAV correctly; (3) as a result, the previously reported NAVs were unreliable; (4) because of the foregoing, the Fund would halt redemptions and liquidate its assets; and (5) as a result, the Prospectuses were materially false and/or misleading and failed to state information required to be stated therein.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP